Drug Profile
Research programme: cancer therapeutics - Avicenna
Alternative Names: DAV0602Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Avicenna Pharma Development
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in United Arab Emirates (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in United Arab Emirates (PO, Tablet)
- 03 Jun 2010 Preclinical trials in Glioblastoma in United Arab Emirates (IV)